ArticleJournal of experimental & clinical cancer research : CR2012
Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas.
Article in Journal of experimental & clinical cancer research : CR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 38 citations in OpenAlex.
- Bending the boundaries: the many facets of endophilin-As from membrane dynamics to disease.Cellular and molecular life sciences : CMLS · 2025Review
- JMJD6 Autoantibodies as a Potential Biomarker for Inflammation-Related Diseases.International journal of molecular sciences · 2024Article
- Biology of endophilin and it's role in disease.Frontiers in immunology · 2023Review
- Investigating Glioblastoma Multiforme Sub-Proteomes: A Computational Study of CUSA Fluid Proteomic Data.International journal of molecular sciences · 2022Article
- Serum anti-SERPINE1 antibody as a potential biomarker of acute cerebral infarction.Scientific reports · 2021Article
- Identification of serum anti-striatin 4 antibodies as a common marker for esophageal cancer and other solid cancers.Molecular and clinical oncology · 2021Article
- Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke.BMC medicine · 2021Article
- Anti-FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancer.Cancer science · 2021Article
- Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases.Cancer science · 2020Article
- Association between serum anti‑ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension.International journal of molecular medicine · 2020Article
- Identification of Novel Native Autoantigens in Rheumatoid Arthritis.Biomedicines · 2020Article
- Anti-FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinoma.Cancer science · 2019Article
- Identification of specific and common diagnostic antibody markers for gastrointestinal cancers by SEREX screening using testis cDNA phage library.Oncotarget · 2018Article
- Elevation of autoantibody level against PDCD11 in patients with transient ischemic attack.Oncotarget · 2018Article
- Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction.Oncotarget · 2018Article
- Linking common non-coding RNAs of human lung cancer and M. tuberculosis.Bioinformation · 2018Article
- SH3GL1 inhibition reverses multidrug resistance in colorectal cancer cells by downregulation of MDR1/P-glycoprotein via EGFR/ERK/AP-1 pathway.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis.Journal of experimental & clinical cancer research : CR · 2015Article
- Circulating anti-filamin C autoantibody as a potential serum biomarker for low-grade gliomas.BMC cancer · 2014Article
- Serological identification of URGCP as a potential biomarker for glioma.CNS neuroscience & therapeutics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlioma is the most common primary malignant central nervous system tumor in adult, and is usually not curable in spite of various therapeutic approaches. Clarification of the oncogenic process in its early stage is important for the diagnosis and effective therapy.
methodsIn the present study, we used the serological identification of antigens by recombinant cDNA expression cloning (SEREX) to explore the subtle changes of the protein expression in low-grade glioma. The levels of serum autoantibodies to the SEREX-identified glioma-related antigens were analyzed by ELISA, and the epitope site was identified using deletion mutants and overlap peptide array. Changes in the serum autoantibody levels were examined in the rat glioma model using C6 and 9 L glioma cell lines.
resultsWe identified 31 glioma-related antigens by SEREX. Among them, the serum level of autoantibody to src-homology 3-domain GRB2-like 1 (SH3GL1) was significantly higher in patients with low-grade glioma than healthy volunteers or high-grade gliomas. The 10 amino-acids at the C-terminal were identified as the epitope site by the overlap peptide array and the ELISA using deletion mutants. The tissue expression of SH3GL1 protein increased in proportion to glioma progression. The rat glioma models confirmed the increase of anti-SH3GL1 autoantibody level in the early stage and the suppression in the late stage.
conclusionSH3GL1 may be involved in the oncogenic process of gliomas and effectively elicit an autologous antibody response in low-grade gliomas. The immunological reaction to SH3GL1 would contribute to the establishment of a novel diagnostic and therapeutic target for gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.